Valuation Fate Therapeutics, Inc. Börse Stuttgart
Stocks
F6T
US31189P1021
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.596 EUR | -1.37% |
|
+0.84% | +216.27% |
Company Valuation: Fate Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,587 | 980.4 | 368.8 | 187.9 | 113.3 | 348.5 | - | - |
| Change | - | -82.45% | -62.39% | -49.04% | -39.69% | 207.48% | - | - |
| Enterprise Value (EV) | 4,971 | 544.2 | 53.6 | -118.8 | 113.3 | 348.5 | 348.5 | 348.5 |
| Change | - | -89.05% | -90.15% | -321.66% | 195.41% | 207.48% | 0% | 0% |
| P/E | -26.1x | -3.47x | -2.28x | -1.01x | -0.85x | -2.76x | -2.9x | -2.78x |
| PBR | 8.25x | 2.03x | 0.98x | 0.59x | - | - | - | - |
| PEG | - | -0.1x | 0.1x | - | 0x | 0.47x | 0.62x | -0.64x |
| Capitalization / Revenue | 100x | 10.2x | 5.8x | 13.8x | 17.1x | 66.4x | 66.6x | 79.7x |
| EV / Revenue | 0x | 0x | 0x | -0x | 0x | 66.4x | 66.6x | 79.7x |
| EV / EBITDA | -0x | -0x | -0x | 0x | -0x | -2.54x | -2.27x | - |
| EV / EBIT | -0x | -0x | -0x | 0x | -0x | -2.47x | -2.22x | -1.94x |
| EV / FCF | -0x | -0x | -0x | 0x | -0x | -3.46x | -2.82x | -2.59x |
| FCF Yield | -3.82% | -28.9% | -37.5% | -65.8% | -98.8% | -28.9% | -35.5% | -38.5% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.24 | -2.91 | -1.64 | -1.64 | -1.15 | -1.082 | -1.031 | -1.076 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 55.85 | 96.3 | 63.53 | 13.63 | 6.646 | 5.247 | 5.236 | 4.375 |
| EBITDA 1 | -211.1 | -294.6 | -172.2 | -191.3 | -134.8 | -137 | -153.2 | - |
| EBIT 1 | -217 | -308.4 | -190.5 | -210.3 | -147.7 | -141.3 | -156.7 | -179.8 |
| Net income 1 | -212.2 | -281.7 | -160.9 | -186.3 | -136.3 | -132.7 | -148 | -173.4 |
| Net Debt | -615.9 | -436.2 | -315.2 | -306.7 | - | - | - | - |
| Reference price 2 | 58.510 | 10.090 | 3.740 | 1.650 | 0.983 | 2.990 | 2.990 | 2.990 |
| Nbr of stocks (in thousands) | 95,494 | 97,170 | 98,602 | 113,894 | 115,352 | 116,559 | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/26/24 | 3/5/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.06x | 6.16x | 13.43x | 1.6% | 53.54B | |
| 32.54x | 8.23x | 25.52x | 0.06% | 54.18B | |
| -41.84x | 13.68x | -39.9x | -.--% | 23.66B | |
| -17.97x | 4.21x | -7.37x | -.--% | 22.78B | |
| 24.64x | 4.81x | 12.68x | -.--% | 19.54B | |
| 25.1x | 4.86x | 15.83x | -.--% | 17.82B | |
| 48x | 19.5x | 50.21x | 0.08% | 16.01B | |
| -526.19x | 37.05x | -4130.99x | -.--% | 15.37B | |
| 17.61x | 5.12x | 11.91x | -.--% | 14.09B | |
| Average | -46.45x | 11.51x | -449.85x | 0.19% | 26.33B | |
| Weighted average by Cap. | -19.85x | 9.83x | -257.40x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- FATE Stock
- F6T Stock
- Valuation Fate Therapeutics, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
